Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: SLAS Discov. 2019 Jul 30;25(1):79–86. doi: 10.1177/2472555219860771

Figure 3.

Figure 3.

Two lead FDA drugs. (A) Pentamidine exhibited more than 100-fold selective inhibition of HPV16-PsV infection (IC50 ≤ 0.002 μM) compared with cell viability (IC50 = 0.08 μM). (B) Securinine exhibited 90-fold selective inhibition of HPV 16-PsV infection (IC50 = 9 μM) compared with cell viability (IC50 = 42.0 μM).